Literature DB >> 11950844

A short segment of the R domain of cystic fibrosis transmembrane conductance regulator contains channel stimulatory and inhibitory activities that are separable by sequence modification.

Junxia Xie1, Lynn M Adams, Jiying Zhao, Thomas A Gerken, Pamela B Davis, Jianjie Ma.   

Abstract

The regulatory (R) domain of the cystic fibrosis transmembrane conductance regulator (CFTR) contains consensus phosphorylation sites for cAMP-dependent protein kinase (PKA) that are the basis for physiological regulation of the CFTR chloride channel. A short peptide segment in the R domain with a net negative charge of B9 (amino acids 817-838, NEG2) and predicted helical tendency is shown to play a critical role in CFTR chloride channel function. Deletion of NEG2 from CFTR completely eliminates the PKA dependence of channel activity. Exogenous NEG2 peptide interacts with CFTR to exert both stimulatory and inhibitory effects on the channel function. The NEG2 peptide with sequence scrambled to remove helical tendencies also inhibits channel function, but does not stimulate. Similar results are found for a NEG2 peptide whose helical structure is disrupted by a proline residue. When six of the negatively charged carboxylic acid residues are replaced by their cognate amides, reducing net negative charge to B3, but increasing helical propensity as assessed by circular dichroism, the peptide stimulates CFTR channel function, but does not inhibit. We speculate that the NEG2 region interacts with other cytosolic domains of CFTR to control opening and closing transitions of the chloride channel.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950844     DOI: 10.1074/jbc.M201661200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  The inhibition mechanism of non-phosphorylated Ser768 in the regulatory domain of cystic fibrosis transmembrane conductance regulator.

Authors:  Guangyu Wang
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

2.  Phosphorylation of CFTR by PKA promotes binding of the regulatory domain.

Authors:  Valerie Chappe; Thomas Irvine; Jie Liao; Alexandra Evagelidis; John W Hanrahan
Journal:  EMBO J       Date:  2005-07-07       Impact factor: 11.598

3.  Protein kinase A phosphorylation potentiates cystic fibrosis transmembrane conductance regulator gating by relieving autoinhibition on the stimulatory C terminus of the regulatory domain.

Authors:  Jeng-Haur Chen
Journal:  J Biol Chem       Date:  2020-02-26       Impact factor: 5.157

4.  A SAXS-based ensemble model of the native and phosphorylated regulatory domain of the CFTR.

Authors:  Carlotta Marasini; Lauretta Galeno; Oscar Moran
Journal:  Cell Mol Life Sci       Date:  2012-10-04       Impact factor: 9.261

5.  CFTR-SLC26 transporter interactions in epithelia.

Authors:  Peying Fong
Journal:  Biophys Rev       Date:  2012-02-15

Review 6.  The gating of the CFTR channel.

Authors:  Oscar Moran
Journal:  Cell Mol Life Sci       Date:  2016-10-01       Impact factor: 9.261

Review 7.  Dynamics intrinsic to cystic fibrosis transmembrane conductance regulator function and stability.

Authors:  P Andrew Chong; Pradeep Kota; Nikolay V Dokholyan; Julie D Forman-Kay
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

8.  Regulation of activation and processing of the cystic fibrosis transmembrane conductance regulator (CFTR) by a complex electrostatic interaction between the regulatory domain and cytoplasmic loop 3.

Authors:  Guangyu Wang; Dayue Darrel Duan
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

9.  Regulation of CFTR trafficking by its R domain.

Authors:  Christopher M Lewarchik; Kathryn W Peters; Juanjuan Qi; Raymond A Frizzell
Journal:  J Biol Chem       Date:  2008-08-11       Impact factor: 5.157

10.  NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR.

Authors:  Voula Kanelis; Rhea P Hudson; Patrick H Thibodeau; Philip J Thomas; Julie D Forman-Kay
Journal:  EMBO J       Date:  2009-11-19       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.